Stockscreener 앱 받기
53.53
2.46%
-1.35
시간 외 거래:
53.22
-0.31
-0.58%
전일 마감가:
$54.88
열려 있는:
$55.04
하루 거래량:
1.47M
Relative Volume:
0.46
시가총액:
$4.87B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-19.12
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
+0.87%
1개월 성능:
-17.34%
6개월 성능:
+22.72%
1년 성능:
+10.97%
1일 변동 폭
$53.25
$55.30
1주일 범위
$52.07
$55.30
52주 변동 폭
$30.04
$71.13
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
53.53 | 4.99B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
How to track smart money flows in CRISPR Therapeutics AGMarket Activity Report & Weekly Return Optimization Plans - Newser
T. Rowe Price Investment Management Inc. Reduces Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
What machine learning models say about CRISPR Therapeutics AG2025 Pullback Review & Free Weekly Chart Analysis and Trade Guides - Newser
Vanguard Group Inc. Boosts Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
Published on: 2025-08-27 20:44:20 - Newser
Statistical indicators supporting CRISPR Therapeutics AG’s strengthWeekly Market Report & Daily Chart Pattern Signals - Newser
Can trapped investors hope for a rebound in CRISPR Therapeutics AGJuly 2025 Gainers & Growth Focused Entry Reports - Newser
When is the best time to exit CRISPR Therapeutics AGWeekly Profit Analysis & Trade Opportunity Analysis Reports - Newser
Comparing CRISPR Therapeutics AG in custom built stock radarsTrade Analysis Summary & Long-Term Capital Growth Strategies - Newser
Technical analysis overview for CRISPR Therapeutics AG stockJuly 2025 Macro Moves & Stepwise Trade Signal Implementation - Newser
Predicting CRISPR Therapeutics AG trend using moving averagesQuarterly Portfolio Report & Precise Entry and Exit Recommendations - Newser
CRISPR Therapeutics: A Speculative Buy With Promising Potential Ahead (CRSP) - Seeking Alpha
Multi asset correlation models including CRISPR Therapeutics AGStock Surge & Free Safe Entry Trade Signal Reports - Newser
Charles Schwab Investment Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
Is it time to cut losses on CRISPR Therapeutics AGJuly 2025 Weekly Recap & Fast Momentum Entry Tips - Newser
Is CRISPR Therapeutics AG stock reversal real or fakeStop Loss & High Accuracy Swing Entry Alerts - Newser
What makes CRISPR Therapeutics AG stock price move sharply2025 Market Outlook & Capital Efficient Trade Techniques - Newser
CRISPR Therapeutics AG recovery potential after sell offJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
Analyzing recovery setups for CRISPR Therapeutics AG investors2025 Earnings Impact & Low Volatility Stock Recommendations - Newser
Technical Models Detect Momentum Build in CRISPR Therapeutics AGJuly 2025 PreEarnings & Daily Momentum Trading Reports - 더경남뉴스
Crispr Therapeutics: Sell Before It's Too Late (NASDAQ:CRSP) - Seeking Alpha
H.C. Wainwright Lifts CRISPR Therapeutics’ (CRSP) Price Target on CASGEVy Sales Growth - MSN
CRISPR Therapeutics Raises Price Target to $80 on CASGEVy Sales Growth - AInvest
Stop Loss: Does CRISPR Therapeutics AG have pricing powerJuly 2025 Final Week & AI Forecast for Swing Trade Picks - sundaytimes.kr
Is CRISPR Therapeutics AG stock bottoming outJuly 2025 Reactions & Breakout Confirmation Trade Signals - Newser
Will Volume Confirm Reversal in CRISPR Therapeutics AGPortfolio Risk Summary & Reliable Intraday Trade Alerts - 더경남뉴스
Crispr Therapeutics AG (CRSP) Gets a Hold from Bernstein - The Globe and Mail
CRISPR Therapeutics AG Charts Flash Early Recovery Signals2025 Volume Leaders & Verified High Yield Trade Plans - beatles.ru
Historical volatility pattern of CRISPR Therapeutics AG visualizedIPO Watch & Advanced Swing Trade Entry Plans - Newser
CRISPR Therapeutics (CRSP) Reports Increase In Q2 Revenue Despite Wider Net Losses - Yahoo Finance
Fox Run Management L.L.C. Invests $629,000 in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock - Yahoo Finance
CRISPR Therapeutics AG $CRSP Shares Acquired by EverSource Wealth Advisors LLC - MarketBeat
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN
Watch for Trend Continuation in CRISPR Therapeutics AG Next WeekJuly 2025 Rallies & Free AI Powered Buy and Sell Recommendations - thegnnews.com
Vestmark Advisory Solutions Inc. Has $7.67 Million Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Bernstein Remains a Hold on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN
What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? - Insider Monkey
CRISPR-based therapies signal a new direction in tackling infectious diseases - Clinical Trials Arena
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
8.06%
자본화:
|
볼륨(24시간):